- Home
- PTC vs INCY Comparison
PTC vs INCY Comparison
Compare PTC & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTC | INCY |
|---|---|---|
| Founded | 1985 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4B | 17.0B |
| IPO Year | 1995 | 1994 |
Fundamental Metrics
Financial Performance| Metric | PTC | INCY |
|---|---|---|
| Price | $155.62 | $92.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 22 |
| Target Price | ★ $195.18 | $101.10 |
| AVG Volume (30 Days) | 1.0M | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 94.87 | ★ 4173.33 |
| EPS | 1.39 | ★ 6.41 |
| Revenue | $2,739,226,000.00 | ★ $3,394,635,000.00 |
| Revenue This Year | $4.26 | $10.97 |
| Revenue Next Year | $6.72 | $10.24 |
| P/E Ratio | $113.27 | ★ $14.35 |
| Revenue Growth | ★ 19.18 | 13.67 |
| 52 Week Low | $133.38 | $53.56 |
| 52 Week High | $219.69 | $112.29 |
Technical Indicators
Market Signals| Indicator | PTC | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 44.52 | 31.64 |
| Support Level | $147.43 | $82.66 |
| Resistance Level | $163.54 | $92.86 |
| Average True Range (ATR) | 4.16 | 2.46 |
| MACD | 0.19 | -0.75 |
| Stochastic Oscillator | 29.24 | 7.74 |
Price Performance
Historical ComparisonAbout PTC PTC Inc.
PTC is a US-based global company that offers high-end computer-assisted design, product lifecycle management, and augmented reality solutions that industrial manufacturers commonly use on factory floors. Founded in 1985, PTC is a major player in parametric design and serves some of the world's most well-known equipment manufacturers, such as Caterpillar, Garmin, and Thermo Fisher.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.